Sanofi (SNY): Price to Earnings Adjusted for Growth Rate

Symbol and logo of brand Sanofi (SNY)

Sanofi is betting on advanced biotechnologies within the vaccination and immunology segment. The PEG ratio confirms the asset's value dynamics, with the latest reading standing at 1.23. Diversification of the rare disease portfolio minimizes patent risks, while a steady cash flow ensures full funding for R&D and stable dividend payments to shareholders.

Sanofi Group - SNY PEG Multiple (period 07/04/2022 - 11/11/2026)

Metric breakdowns and analytics for Sanofi (SNY)

- share price and consensus valuation forecast:
Price Performance Chart Sanofi SA|SNY - Price Target Chart
- stock exchange capitalization data:
Market Value Sanofi Aventis|SNY - Total Company Value
- shareholders' equity book value data:
Net Assets per Single Share Sanofi|SNY - Book Capitalization|Capitalization to Book Value Ratio sanofi.com|SNY - Company Total Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Coefficient Sanofi|SNY - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio sanofi.com|SNY - Company Aggregate Debts|Debt to Net Assets Sanofi Aventis|SNY - Company Long-Term Debt|Short-Term Debt Volume Sanofi|Quick Ratio sanofi.com
- financial results and valuation multiples details:
SNY - Company Net Income|Net Profit Forecast Sanofi|SNY - Price to Earnings Ratio|Projected Price to Earnings Ratio Sanofi Group|SNY - PEG Multiple|Company Value to Operating Income Before Depreciation Ratio Sanofi Aventis|SNY - Operating profit EBITDA|Net earnings per share for the last four quarters Sanofi|SNY - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months sanofi.com|SNY - Earnings per share growth in current year|Projected earnings per share growth rate for next year Sanofi
General company analysis:Sanofi
Core merchandise of Sanofi SA

Explosive demand for Dupixent provides Sanofi (SNY) with real operational growth that should be weighed against the market value of its shares. By analyzing the PEG ratio, an investor assesses the P/E ratio relative to earnings growth rates: a value below one signals that the business is undervalued relative to its momentum, allowing one to separate fundamental strength from temporary market noise on this chart.

Competitors of Sanofi

LLY (Lilly) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Abbvie ABBV|AstraZeneca Corp. (AZN) - Price to Earnings Adjusted for Growth Rate|NVS - Price/Earnings to Growth Ratio|MRK: Price/Earnings to Growth Ratio|NVO: PEG Multiple|Growth-Adjusted P/E Ratio AMGN|PFE (Pfizer Corporation) - PEG Multiple|Bristol-Myers Squibb Co. (BMY) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio GSK plc (GSK)|takeda.com - Growth-Adjusted P/E Ratio|PEG Multiple TEVA (Teva Pharmaceutical Industries Limited)|Price to Net Income Growth Ratio Dr. Reddy's Laboratories Limited|VTRS - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income Roivant Corp ROIV|ZLAB: PEG Multiple|bauschhealth.com (BHC) - PEG Multiple|Price/Earnings to Growth Ratio Cosmos Health